Trial Profile
A Phase I Pilot Study of SBRT and Concurrent Docetaxel for Reirradiation of Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 26 Nov 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary)
- Indications Head and neck cancer
- Focus Adverse reactions
- 21 Nov 2019 Status changed from recruiting to discontinued.
- 30 Jun 2014 New trial record